Steven T Miller

This inventor holds 28 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in RNA Interference Therapy. Top assignees: Alcon Research, Ltd., Alcon Universal Ltd., Arrowhead Pharmaceuticals, Inc.. Active years: 1994-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven T Miller. Retrieved from https://idiyas.com/inventor/steven-t-miller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 4)

% Patents Active = 64.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

Arrowhead Pharmaceuticals, Inc.

patents

4. 3 out of 449

Alcon Laboratories, Inc.

Arrowhead Research Corporation

patents

7. 2 out of 834,708

Other

patents

Years Active: 1994-2017

Loading Chart...

Areas of Expertise:

RNA Interference

Phosphodiesterase Inhibition

Histamine Receptor H1

Ocular Disorders

Tumor Necrosis Factor

Spleen Tyrosine Kinase

Inflammatory Diseases

Allergic Conditions

Disulfide Derivatives

Mast Cell Degranulation

Dry Eye Treatment

Hydroxyeicosatetraenoic Acid

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9765340 - RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders (2017-09-19),

2. 9745585 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2017-08-29),

3. 9453220 - RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders (2016-09-27),

4. 9447419 - RNAi-mediated inhibition of tumor necrosis factor α-related conditions (2016-09-20),

5. 9371529 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions (2016-06-21),

6. 9206428 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2015-12-08),

7. 8865671 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions (2014-10-21),

8. 8673873 - RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders (2014-03-18),

9. 8618278 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2013-12-31),

10. 8541389 - RNAi-mediated inhibition of tumor necrosis factor α-related conditions (2013-09-24),

11. 8222227 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2012-07-17),

12. 8048863 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions (2011-11-01),

13. 8017592 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2011-09-13),

14. 7906512 - 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases (2011-03-15),

15. 7799778 - 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases (2010-09-21),

Title: The Inventor Steven T Miller from Arlington, TX

Introduction: Steven T Miller is a prolific inventor based in Arlington, Texas, known for his groundbreaking contributions to various fields.

Latest Patents: Steven T Miller holds several patents in the areas of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: Throughout his career, Steven T Miller has demonstrated a keen ability to transform creative concepts into tangible inventions that have made a significant impact on industries worldwide.

Collaborations: Steven T Miller has collaborated with leading companies, research institutions, and universities to further develop and commercialize his inventions, solidifying his reputation as a visionary inventor.

Conclusion: Steven T Miller's passion for innovation and his relentless pursuit of excellence continue to drive his success in the world of inventions, making him a respected figure in the field.

Profile summary based on public USPTO records.